As the year comes to a close, we wanted to share some of our progress since our August 2016 newsletter. Some highlights include:

  • Enrollment in our ongoing Phase 2/3 clinical trial, Toca 5, is going very well at 64 leading brain cancer hospitals in the United States, Canada, Israel and South Korea.
  • New clinical and preclinical data were presented at key scientific conferences, including updated tumor response and survival data.
  • We strengthened our leadership team with the appointment of Martin “Marty” Duvall as our CEO. Our co-founder and former CEO, Harry Gruber, M.D., is now our president of research and development, as well as continuing as a key member of our board of directors.
  • François, a patient in one of our Phase 1 trials, shared his inspiring story of hope and survival.
  • Our science, progress and patient stories continue to be reported by the media.
  • The first patient was enrolled in our new trial evaluating intravenously delivered Toca 511 in metastatic cancers.

We wish you a wonderful holiday season and happy New Year, and remain grateful for your continued support in our fight against cancer!

The Tocagen Team